PDCD1 and hepatocellular carcinoma: Recently, two programmed cell death protein 1 (PD-1) inhibitors, pembrolizumab [3] and nivolumab [4], were approved for HCC treatment in patients who experienced progression after taking sorafenib, but their response rates (approximately 20%) were also unsatisfactory [5].